financetom
Business
financetom
/
Business
/
Hims & Hers Health Stock Is Rising Tuesday: What's Going On?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Hims & Hers Health Stock Is Rising Tuesday: What's Going On?
Jun 3, 2025 6:10 AM

Hims & Hers Health Inc ( HIMS ) shares are trading higher Tuesday after the company announced an acceleration of its global expansion through the acquisition of ZAVA.

What Happened: Hims & Hers Health ( HIMS ) will acquire ZAVA, which operates a popular digital health platform in Europe. The acquisition will expand the company’s footprint in the United Kingdom and will mark its official entry into Germany, France and Ireland, with more markets anticipated soon.

Zava serves more than 1.3 million active customers and delivered close to 2.3 million in-house medical consultations last year. Hims & Hers plans to expand offerings in Europe by bringing personalized healthcare to new Zava members across dermatology, weight loss, sexual health and mental health.

“The demand for simpler, more personalized healthcare is universal. By leveraging ZAVA’s established European presence, cutting-edge technology, and deep customer understanding, we’re poised to fundamentally transform access to care for millions across Europe,” said Andrew Dudum, founder and CEO of Hims & Hers.

“Whether in rural towns, vibrant cities, or remote communities across Europe, people battling widespread, often silent chronic conditions like obesity, depression, and more will have access to the personalized, high-quality care they deserve.”

Hims & Hers said it expects the deal to be accretive by 2026. The acquisition is expected to close in the second half of 2025 and will be funded completely with cash from the company’s balance sheet. The company noted that it will share more about offerings and planned rollouts in the coming months.

HIMS Price Action: Hims & Hers Health ( HIMS ) shares were up 6.34% at $60.36 at the time of publication Tuesday, according to Benzinga Pro.

Read Next:

Trump Sets July 8 Deadline For Trade Deals, Demands Best Offers From Global Partners By Wednesday: Report

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Healthcare Realty Trust, KKR Enter Joint Venture to Invest in Medical Outpatient Buildings
Healthcare Realty Trust, KKR Enter Joint Venture to Invest in Medical Outpatient Buildings
May 6, 2024
08:32 AM EDT, 05/06/2024 (MT Newswires) -- Healthcare Realty Trust ( HR ) said Monday it will contribute 12 properties valued at $382.5 million to a seed portfolio in a new joint venture with asset manager KKR to invest in medical outpatient buildings. Under the terms of the joint venture, Healthcare Realty ( HR ) expects to receive about $300...
Sector Update: Consumer
Sector Update: Consumer
May 6, 2024
08:27 AM EDT, 05/06/2024 (MT Newswires) -- Consumer stocks were advancing pre-bell Monday, with the Consumer Staples Select Sector SPDR Fund (XLP) up 0.2% and the Consumer Discretionary Select Sector SPDR Fund (XLY) 0.6% higher. Freshpet ( FRPT ) shares jumped 14% after the company reported Q1 earnings of $0.37 per diluted share, swinging from a loss of $0.52 a...
BRIEF-Hub International Has Acquired Assets Of William R. Cargill Insurance Agency, Inc. (Cargill Insurance)
BRIEF-Hub International Has Acquired Assets Of William R. Cargill Insurance Agency, Inc. (Cargill Insurance)
May 6, 2024
May 6 (Reuters) - HUB International Ltd: * HUB INTERNATIONAL LTD - HAS ACQUIRED ASSETS OF WILLIAM R. CARGILL INSURANCE AGENCY, INC. (CARGILL INSURANCE) * HUB INTERNATIONAL LTD - TERMS OF TRANSACTION WERE NOT DISCLOSED. Source text for Eikon: Further company coverage: ...
Krystal Biotech Swings to Q1 Profit -- Shares Fall
Krystal Biotech Swings to Q1 Profit -- Shares Fall
May 6, 2024
08:35 AM EDT, 05/06/2024 (MT Newswires) -- Krystal Biotech ( KRYS ) reported Q1 earnings Monday of $0.03 per diluted share, swinging from a net loss of $1.76 a year earlier. Analysts polled by Capital IQ expected $0.15. Net product revenue for the quarter ended March 31 was $45.3 million. The biotech company did not report revenue last year. Analysts...
Copyright 2023-2026 - www.financetom.com All Rights Reserved